School of Medicine
Showing 621-640 of 1,054 Results
-
Mark Mercola
Professor of Medicine (Cardiovascular) and, by courtesy, of Chemical and Systems Biology
BioDr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.
Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative high throughput assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.
Prof. Mercola received an NIH MERIT award for his work on heart formation. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the National Institutes of Health (NIH), California Institute for Regenerative Medicine, Phospholamban Foundation and Fondation Leducq. -
Thomas Charles Merigan M.D.
George E. and Lucy Becker Professor of Medicine, Emeritus
Current Research and Scholarly InterestsI am now emeritus and only participate in university activities through advising my former trainees who have joined the faculty.
-
Everett Meyer
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy), of Pediatrics (Stem Cell Transplantation) and, by courtesy, of Surgery (Abdominal Transplantation)
Current Research and Scholarly InterestsResearch focus in T cell immunotherapy and T cell immune monitoring using high-throughput sequencing and genomic approaches, with an emphasis on hematopoietic stem cell transplantation, the treatment of graft-versus-host disease and immune tolerance induction.
-
Timothy Meyer
Stanford University Professor of Nephrology, Emeritus
Current Research and Scholarly InterestsInadequate removal of uremic solutes contributes to widespread illness in the more than 500,000 Americans maintained on dialysis. But we know remarkably little about these solutes. Dr. Meyer's research efforts are focused on identifying which uremic solutes are toxic, how these solutes are made, and how their production could be decreased or their removal could be increased. We should be able to improve treatment if we knew more about what we are trying to remove.
-
Lekha Mikkilineni
Assistant Professor of Medicine (Blood and Marrow Transplantation & Cellular Therapy)
BioDr. Lekha Mikkilineni is a board-certified medical oncologist. She is also an Assistant Professor in the Department of Medicine, Division of Blood & Marrow Transplant and Cellular Therapy.
Dr. Mikkilineni has extensive experience treating blood and bone marrow cancers. She currently provides care through the Bone Marrow Transplant & Cellular Therapy Program at Stanford Health Care. Her clinical focus is multiple myeloma, plasma-cell leukemia, Extramedullary myeloma, high-risk myeloma, CAR T cell therapy, bispecific therapy, amyloidosis, POEMS syndrome, and Waldenstrom’s macroglobunemia.
Dr. Mikkilineni’s research centers on exploring novel CAR T-cell therapies to treat multiple myeloma and to define mechanisms of resistance to immunotherapy. She is particularly focused on understanding how to improve therapies for multiple myeloma patients who have extramedullary disease or high-risk features. Prior to coming to Stanford, she ran phase 1 CAR T-cell trials for multiple myeloma targeting BCMA and SLAMF7 at the National Cancer Institute.
Dr. Mikkilineni received the Conquer Cancer Foundation Young Investigator Award from the American Society of Clinical Oncology for her research focusing on SLAMF7 as a potential target for multiple myeloma. She has received honors and awards for her work at the NCI. She has completed fellowships in hematology/oncology and immunotherapy at the National Heart, Lung, and Blood Institute/National Cancer Institute. She finished her residency in internal medicine at Thomas Jefferson University Hospital. She holds a Master of Science in medical sciences from Boston University and a medical degree from Tulane University.
Dr. Mikkilineni has authored book chapters and published research in numerous high-impact academic journals. She has presented her findings through oral and poster presentations at national and international conferences. -
David Miklos
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsDr. Miklos is the Chief of BMT & Cell Therapy Program. He leads clinical trials treating patients with lymphoma. His correlative research studies: 1) tumor antigen quantification, 2) single cell functional product characterization, 3) CAR-FACS immune phenotyping of blood and tumor, and identifying mechanisms for CAR-T treatment Failure including antigen loss, CAR-T exhaustion, and CAR suppression.
-
Carlos Milla
Professor of Pediatrics (Pulmonary Medicine) and, by courtesy, of Medicine (Pulmonary and Critical Care Medicine)
Current Research and Scholarly InterestsAt Stanford University I developed and currently direct the CF Translational Research Center. The overarching goal of the center is to provide the groundwork to streamline, accelerate, and promote the translation of basic discoveries into effective therapies and interventions to benefit patients affected by cystic fibrosis. My laboratory group currently has three main lines of investigation: respiratory cell biology in CF; remote biochemical monitoring; and lung physiology in young children.
-
Arnold Milstein
Professor of Medicine (General Medical Discipline)
Current Research and Scholarly InterestsDesign national demonstration of innovations in care delivery that provide more with less. Informed by research on AI-assisted clinical workflow, positive value outlier analysis and triggers of loss aversion bias among patients and clinicians.
Research on creation of a national index of health system productivity gain. -
Vijay Mirmira
Adjunct Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioDr. Mirmira believes that excellent communication leads to excellent care, and is dedicated to the health and well-being of his patients and their families. He is fluent in English, Hindi, Tamil and Kannada and has working knowledge of Urdu and Telugu. Apart from enjoying practicing the full scope of family medicine, Dr. Mirmira's special interests include diabetes and thyroid disorders, and pediatric illnesses. He likes to travel and read fiction in his free time.
-
Beverly S. Mitchell, M.D.
George E. Becker Professor of Medicine
Current Research and Scholarly InterestsBeverly Mitchell's research relates to the development of new therapies for hematologic malignancies, including leukemias and myelodsyplastic syndromes. She is interested in preclinical proof of principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. She is also interested in the translation of these studies into clinical trials.
-
Maha Abdalla Mohamed, MD, FACP, FAST
Clinical Associate Professor, Medicine - Nephrology
BioDr. Mohamed is a board-certified, fellowship-trained nephrologist with the Kidney and Pancreas Transplant Program at Stanford Healthcare. She is a clinical associate professor in the Department of Medicine, Division of Nephrology.
Dr. Mohamed specializes in kidney and pancreas transplant outcomes and kidney transplant health equity. Conditions she treats include allografts rejection, recipient BK virus and CMV infection, and post-transplant lymphoproliferative disorder management. Dr. Mohamed is known for her personalized and comprehensive approach to patient care. She takes the time to understand her patients’ unique health needs and creates tailored care plans that fit their lifestyles.
Dr. Mohamed’s research interests include examining new approaches to improving kidney transplant long-term outcome including kidney transplant rejection and infection. She also seeks to develop better screening and monitoring guidance to help reduce post-transplant BK virus and CMV infection.
Dr. Mohamed’s published work can be found in peer-reviewed journals such as Clinical Transplantation, Transplant Infectious Disease and Transplantation. She has presented to her peers at international, national, and regional meetings, including at the American Transplant Congress and the American Society of Nephrology. She has also been invited to speak multiple times at King Faisal Hospital in Rwanda as well as in Kingdom of Saudi Arabia on topics like post-transplant lymphoproliferative disorder, update in kidney transplant rejection, and update in living-donor kidney transplantation.
Dr. Mohamed is a faculty fellow of Stanford Center for Innovation in Global Health, fellow of the American Society of Transplantation, a board of managers member of the AST Transplant Nephrology Fellowship Training Accreditation Program, member of the International Society of Nephrology and the American Society of Nephrology. -
Minal Moharir
Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioI was born, raised, and trained in Nashik, India where I completed my formal Medical Education before moving to New York City where I completed my residency in Internal Medicine at New York Downtown Hospital in New York, NY. My interests are in preventative medicne, health and wellness, occupational and environmental safety. In Stanford's Occupational Health Department, I practice clinical occupational medicine while working toward identifying health and safety issues within our enviroment to prevent further injury and illness to our employees.
-
Tamara Montacute, MD, MPH
Clinical Associate Professor, Medicine - Primary Care and Population Health
BioTamara Kailoa Montacute is a board certified Family Medicine physician. She enjoys taking care of the entire family (including kids), and has special interest in women’s health, adolescent health, community health, chronic disease management, mental health and office based procedures. She also speaks Spanish.
She was born in New Zealand, grew up in England and moved to Seattle when she was twelve. Prior to attending medical school at Stanford, she completed her Masters in Public Health at Columbia University and spent several years working on public health programs in Mexico, Panama, Ethiopia and Rwanda. After medical school, she completed a Family Medicine Residency at O’Connor Hospital in San Jose. She is the co-medical director of Arbor Free Clinic, teaches several primary care focused medical student courses and spends part of her time caring for patients at the Samaritan House Free Clinics in Redwood City and San Mateo.
Outside the clinic, she enjoys hiking, biking, gardening and playing with her daughter and 2 dogs.
